课题基金 / 基金详情

ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE INTERFERON ALPHA IN HCL

ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE INTERFERON ALPHA IN HCL
盐酸中的交替 2-DCF 和重组白细胞干扰素 α
批准号:
2464504
负责人:
J E JANIK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

J E JANIK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We administered dCF and IFN-alpha sequentially to pts. with HCL in an attempt to improve the response rate and duration observed in earlier studies using each drug alone. In this study, we evaluated pts. for response by performing bilateral iliac crest bone marrow biopsies and aspirates since the peripheral blood normalizes rapidly after either IFN-alpha or dCF treatment but disease becomes patchy in the bone marrow and might be missed if only unilateral bone marrow biopsies had been performed. Other studies using IFN-alpha or dCF alone used unilateral marrow examinations in evaluating response. Using these more relaxed criteria of response, authors had published high rates of complete remission to dCF. Of 15 pts. entered in our study, 14 are evaluable for response with 1 pt. having diffuse osteosclerosis not being evaluable for marrow response. All pts. had rapid normalization of peripheral blood counts and all 14 marrow-evaluable pts. were found to have very small numbers (less than 5% of total marrow cellularity) of residual hairy cells at the completion of tx. Among the 14 evaluable pts., 4 pts. have developed progressive disease off tx. The single nonevaluable pt. with diffuse osteosclerosis developed anemia with increasing sIL-2R levels consistent with progressive hairy cell leuk- emia. 3 pts. received tx. With 2-chlorodeoxyadenosine and 1 received IFN-alpha. Although the initial response rate to the combination of dCF and IFN appears to be no better than that observed with dCF alone, the response duration may be longer. The remaining pts. continue to be followed for determination of response duration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
  • 批准号:
    3874539
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J E JANIK
  • 依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
  • 批准号:
    3838223
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J E JANIK
  • 依托单位:
海外基金